Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 regimens of VIR-2218, VIR-3434, and/or peginterferon alfa-2a in chronic hepatitis B virus infection
2024-513177-48-00Phase 2Completed
- Sponsor
- Vir Biotechnology
- Start
- Sep 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 2 trial of tobevibart, elebsiran, interferon alfa and peginterferon alfa-2a in Chronic Hepatitis B (CHB) (3 arms), sponsored by Vir Biotechnology. Primary endpoints: Treatment-emergent adverse events, Serious adverse events and 2 more. Started Sep 2024; status: completed.
02
Drugs
tobevibartelebsiraninterferon alfapeginterferon alfa-2a
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2024-513177-48-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513177-48-00.